17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects

Tim Lahm, Marjorie Albrecht, Amanda J. Fisher, Mona Selej, Neel G. Patel, Jordan A. Brown, Matthew J. Justice, M. Beth Brown, Mary Van Demark, Kevin M. Trulock, Dino Dieudonne, Jagadeshwar G. Reddy, Robert Presson, Irina Petrache

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Rationale: 17β-Estradiol (E2) attenuates hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension (HPH) through an unknown mechanism that may involve estrogen receptors (ER) or E2 conversion to catecholestradiols and methoxyestradiols with previously unrecognized effects on cardiopulmonary vascular remodeling. Objectives: To determine the mechanism by which E2 exerts protective effects in HPH. Methods: Male rats were exposed to hypobaric hypoxia while treated with E2 (75 μg/kg/d) or vehicle. Subgroups were cotreated with pharmacologic ER- antagonistor with inhibitors of E2-metabolite conversion. Complementary studies were performed in rats cotreated with selective ERα- or ERβ-antagonist. Hemodynamic and pulmonary artery (PA) and right ventricular (RV) remodeling parameters, including cell proliferation, cell cycle, and autophagy, were measured in vivo and in cultured primary rat PA endothelial cells. Measurements and Main Results: E2 significantly attenuated HPH endpoints. Hypoxia increased ERβ but not ERα lung vascular expression. Co-treatment with nonselective ER inhibitor or ERα-specific antagonist rendered hypoxic animals resistant to the beneficial effects of E2 on cardiopulmonary hemodynamics, whereas ERα- and ERβ-specific antagonists opposed the remodeling effects of E2. In contrast, inhibition of E2-metabolite conversion did not abolish E2 protection. E2- treated hypoxic animals exhibited reduced ERK1/2 activation and increased expression of cell-cycle inhibitor p27 Kip1 in lungs and RV, with up-regulation of lung autophagy. E2-induced signaling was recapitulated in hypoxic but not normoxic endothelial cells, and was associated with decreased vascular endothelial growth factor secretion and cell proliferation.

Original languageEnglish
Pages (from-to)965-980
Number of pages16
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume185
Issue number9
DOIs
StatePublished - May 1 2012

Fingerprint

Pulmonary Hypertension
Estrogen Receptors
Estradiol
Lung
Autophagy
Pulmonary Artery
Cell Cycle
Endothelial Cells
Hemodynamics
Cell Proliferation
Ventricular Remodeling
Vasoconstriction
Vascular Endothelial Growth Factor A
Blood Vessels
Up-Regulation
Estrogen Receptor Antagonists

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. / Lahm, Tim; Albrecht, Marjorie; Fisher, Amanda J.; Selej, Mona; Patel, Neel G.; Brown, Jordan A.; Justice, Matthew J.; Brown, M. Beth; Van Demark, Mary; Trulock, Kevin M.; Dieudonne, Dino; Reddy, Jagadeshwar G.; Presson, Robert; Petrache, Irina.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 185, No. 9, 01.05.2012, p. 965-980.

Research output: Contribution to journalArticle

Lahm, T, Albrecht, M, Fisher, AJ, Selej, M, Patel, NG, Brown, JA, Justice, MJ, Brown, MB, Van Demark, M, Trulock, KM, Dieudonne, D, Reddy, JG, Presson, R & Petrache, I 2012, '17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects', American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 9, pp. 965-980. https://doi.org/10.1164/rccm.201107-1293OC
Lahm, Tim ; Albrecht, Marjorie ; Fisher, Amanda J. ; Selej, Mona ; Patel, Neel G. ; Brown, Jordan A. ; Justice, Matthew J. ; Brown, M. Beth ; Van Demark, Mary ; Trulock, Kevin M. ; Dieudonne, Dino ; Reddy, Jagadeshwar G. ; Presson, Robert ; Petrache, Irina. / 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. In: American Journal of Respiratory and Critical Care Medicine. 2012 ; Vol. 185, No. 9. pp. 965-980.
@article{eed7b6537e1c415784c4072abd75e376,
title = "17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects",
abstract = "Rationale: 17β-Estradiol (E2) attenuates hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension (HPH) through an unknown mechanism that may involve estrogen receptors (ER) or E2 conversion to catecholestradiols and methoxyestradiols with previously unrecognized effects on cardiopulmonary vascular remodeling. Objectives: To determine the mechanism by which E2 exerts protective effects in HPH. Methods: Male rats were exposed to hypobaric hypoxia while treated with E2 (75 μg/kg/d) or vehicle. Subgroups were cotreated with pharmacologic ER- antagonistor with inhibitors of E2-metabolite conversion. Complementary studies were performed in rats cotreated with selective ERα- or ERβ-antagonist. Hemodynamic and pulmonary artery (PA) and right ventricular (RV) remodeling parameters, including cell proliferation, cell cycle, and autophagy, were measured in vivo and in cultured primary rat PA endothelial cells. Measurements and Main Results: E2 significantly attenuated HPH endpoints. Hypoxia increased ERβ but not ERα lung vascular expression. Co-treatment with nonselective ER inhibitor or ERα-specific antagonist rendered hypoxic animals resistant to the beneficial effects of E2 on cardiopulmonary hemodynamics, whereas ERα- and ERβ-specific antagonists opposed the remodeling effects of E2. In contrast, inhibition of E2-metabolite conversion did not abolish E2 protection. E2- treated hypoxic animals exhibited reduced ERK1/2 activation and increased expression of cell-cycle inhibitor p27 Kip1 in lungs and RV, with up-regulation of lung autophagy. E2-induced signaling was recapitulated in hypoxic but not normoxic endothelial cells, and was associated with decreased vascular endothelial growth factor secretion and cell proliferation.",
author = "Tim Lahm and Marjorie Albrecht and Fisher, {Amanda J.} and Mona Selej and Patel, {Neel G.} and Brown, {Jordan A.} and Justice, {Matthew J.} and Brown, {M. Beth} and {Van Demark}, Mary and Trulock, {Kevin M.} and Dino Dieudonne and Reddy, {Jagadeshwar G.} and Robert Presson and Irina Petrache",
year = "2012",
month = "5",
day = "1",
doi = "10.1164/rccm.201107-1293OC",
language = "English",
volume = "185",
pages = "965--980",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "9",

}

TY - JOUR

T1 - 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects

AU - Lahm, Tim

AU - Albrecht, Marjorie

AU - Fisher, Amanda J.

AU - Selej, Mona

AU - Patel, Neel G.

AU - Brown, Jordan A.

AU - Justice, Matthew J.

AU - Brown, M. Beth

AU - Van Demark, Mary

AU - Trulock, Kevin M.

AU - Dieudonne, Dino

AU - Reddy, Jagadeshwar G.

AU - Presson, Robert

AU - Petrache, Irina

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Rationale: 17β-Estradiol (E2) attenuates hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension (HPH) through an unknown mechanism that may involve estrogen receptors (ER) or E2 conversion to catecholestradiols and methoxyestradiols with previously unrecognized effects on cardiopulmonary vascular remodeling. Objectives: To determine the mechanism by which E2 exerts protective effects in HPH. Methods: Male rats were exposed to hypobaric hypoxia while treated with E2 (75 μg/kg/d) or vehicle. Subgroups were cotreated with pharmacologic ER- antagonistor with inhibitors of E2-metabolite conversion. Complementary studies were performed in rats cotreated with selective ERα- or ERβ-antagonist. Hemodynamic and pulmonary artery (PA) and right ventricular (RV) remodeling parameters, including cell proliferation, cell cycle, and autophagy, were measured in vivo and in cultured primary rat PA endothelial cells. Measurements and Main Results: E2 significantly attenuated HPH endpoints. Hypoxia increased ERβ but not ERα lung vascular expression. Co-treatment with nonselective ER inhibitor or ERα-specific antagonist rendered hypoxic animals resistant to the beneficial effects of E2 on cardiopulmonary hemodynamics, whereas ERα- and ERβ-specific antagonists opposed the remodeling effects of E2. In contrast, inhibition of E2-metabolite conversion did not abolish E2 protection. E2- treated hypoxic animals exhibited reduced ERK1/2 activation and increased expression of cell-cycle inhibitor p27 Kip1 in lungs and RV, with up-regulation of lung autophagy. E2-induced signaling was recapitulated in hypoxic but not normoxic endothelial cells, and was associated with decreased vascular endothelial growth factor secretion and cell proliferation.

AB - Rationale: 17β-Estradiol (E2) attenuates hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension (HPH) through an unknown mechanism that may involve estrogen receptors (ER) or E2 conversion to catecholestradiols and methoxyestradiols with previously unrecognized effects on cardiopulmonary vascular remodeling. Objectives: To determine the mechanism by which E2 exerts protective effects in HPH. Methods: Male rats were exposed to hypobaric hypoxia while treated with E2 (75 μg/kg/d) or vehicle. Subgroups were cotreated with pharmacologic ER- antagonistor with inhibitors of E2-metabolite conversion. Complementary studies were performed in rats cotreated with selective ERα- or ERβ-antagonist. Hemodynamic and pulmonary artery (PA) and right ventricular (RV) remodeling parameters, including cell proliferation, cell cycle, and autophagy, were measured in vivo and in cultured primary rat PA endothelial cells. Measurements and Main Results: E2 significantly attenuated HPH endpoints. Hypoxia increased ERβ but not ERα lung vascular expression. Co-treatment with nonselective ER inhibitor or ERα-specific antagonist rendered hypoxic animals resistant to the beneficial effects of E2 on cardiopulmonary hemodynamics, whereas ERα- and ERβ-specific antagonists opposed the remodeling effects of E2. In contrast, inhibition of E2-metabolite conversion did not abolish E2 protection. E2- treated hypoxic animals exhibited reduced ERK1/2 activation and increased expression of cell-cycle inhibitor p27 Kip1 in lungs and RV, with up-regulation of lung autophagy. E2-induced signaling was recapitulated in hypoxic but not normoxic endothelial cells, and was associated with decreased vascular endothelial growth factor secretion and cell proliferation.

UR - http://www.scopus.com/inward/record.url?scp=84860634134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860634134&partnerID=8YFLogxK

U2 - 10.1164/rccm.201107-1293OC

DO - 10.1164/rccm.201107-1293OC

M3 - Article

C2 - 22383500

AN - SCOPUS:84860634134

VL - 185

SP - 965

EP - 980

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 9

ER -